AbbVie Inc. (NYSE:ABBV)

pills

Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?

After the markets closed Monday, Express Scripts Holding Company (NASDAQ: ESRX) reported its fourth-quarter financial results as $1.39 in earnings per share (EPS) and $26.31 billion in revenue. This is ...
Read Full Story »
Pfizer logo

Jefferies 4 Top Pharmaceutical Stocks to Buy

With the stock market hitting all-time highs, many investors are starting to wonder which sectors still hold value. Although seeming rich, the market continues climbing a wall of worry to ...
Read Full Story »
Pills

Neurocrine Biosciences Announces New Offering

Neurocrine Biosciences Inc. (NASDAQ: NBIX) has announced that it will have another public offering of its common stock. The total offering is expected to raise an aggregate of roughly $225 ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: AbbVie, Alcoa, Apple, Deckers, Dish, Pfizer, Petrobras and More

Stocks were soft on Monday despite OPEC hinting at a faster oil demand recovery than expected. The rally from last week was on the heels of a bad January, and ...
Read Full Story »
Pills

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the costs of some of the drugs on the market today. ...
Read Full Story »
biotech

What to Expect From Gilead Earnings

Tuesday after the markets close, Gilead Sciences Inc. (NASDAQ: GILD) will report its fourth-quarter financial results. Thomson Reuters has consensus estimates of $2.22 in earnings per share (EPS) and $6.72 ...
Read Full Story »
462542665

Are Humira Sales Enough to Lift AbbVie?

AbbVie Inc. (NYSE: ABBV) reported its fourth-quarter financial results Friday before the markets open. This drug manufacturing giant posted earnings per share (EPS) of $0.89 and $5.37 billion in revenue. ...
Read Full Story »
Money background. Close-up.

Gilead Continues to Recover from Express Scripts Loss

After the markets closed on Thursday, Gilead Sciences Inc. (NASDAQ: GILD) was picked up by Anthem Inc. (NYSE: ANTM) to provide its hepatitis C drug as the primary option for ...
Read Full Story »
thumbs up

Is Gilead Already Coming Back Into Favor?

Over the past year, Gilead Sciences Inc. (NASDAQ: GILD) has been a top dog with regards to hepatitis C treatments, pulling in over $6.2 billion in sales for these treatments ...
Read Full Story »
downgrade sign

Analysts Predict Big Value Trap for Gilead Investors

AbbVie Inc. (NYSE: ABBV) and Express Scripts Holding Co. (NASDAQ: ESRX) entered into an exclusive distribution agreement following the U.S. Food and Drug Administration’s (FDA) approval of AbbVie’s hepatitis C ...
Read Full Story »
Pills

What the AbbVie and Express Script Deal Means for Gilead

AbbVie Inc. (NYSE: ABBV) received U.S. Food and Drug Administration (FDA) approval for its hepatitis C drug last Friday, and the drug will directly compete with treatments from Gilead Sciences Inc. ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: ARIAD, FedEx, Genpact, Suncor, Travelers, UPS and More

Stocks were trying to post a recovery on Thursday morning on the heels of three days worth of energy-related selling. Despite a relatively harsh drop, investors have proven over and ...
Read Full Story »
Monkey evil

Top Analyst Upgrades and Downgrades: Harley-Davidson, Lululemon, Nike, SunPower, Walmart and More

Stocks were trying to hold on to gains on Friday morning after a marginal gain in eurozone GDP indicates that quantitative easing is needed over there. The one lesson we ...
Read Full Story »
biotech

4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic

One sad trend that has exploded in the new millennium has been the increase in hepatitis C cases in the Unites States and around the world. One startling fact is ...
Read Full Story »
AT&T logo

The 7 Most Heavily Shorted NYSE Stocks

Here is a look at the seven stocks traded on the New York Stock Exchange with the largest number of shares held short as of October 15. Only one of ...
Read Full Story »